)
Visual
earnings real time
Absci (ABSI) investor relations material
Absci Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status Update summary11 Dec, 2025
Patient Need and Market Opportunity
Androgenetic alopecia (AGA) affects about 80 million Americans and tens of millions globally, causing major psychosocial impacts for both men and women.
Current treatments are outdated, inconvenient, and often ineffective, with less than 10% patient satisfaction.
Over 80% of patients experience strong negative psychological effects, and 87% of men and 69% of women show high interest in ABS-201.
Willingness to pay a premium is high, with a U.S. market opportunity estimated at over $25B and global TAM exceeding $40B.
Scientific Rationale, Preclinical Data, and Mechanism of Action
ABS-201 is an AI-designed prolactin receptor (PRLR) antibody targeting a novel pathway for hair regrowth.
Preclinical studies in mice and primates showed robust, durable hair regrowth and repigmentation, with effects lasting years post-treatment.
Ex vivo human scalp studies confirmed ABS-201 prolongs the anagen phase, stimulates stem cells, increases growth factors IGF-1 and FGF7, and preserves the progenitor cell pool.
The antibody blocks PRL-induced catagen, promotes anagen, and prevents stem cell exhaustion, with activity even without exogenous prolactin.
Safety data from genetic and preclinical toxicology studies are favorable, with no significant adverse effects observed.
Clinical Development and Trial Design
A double-blind, placebo-controlled Phase 1/2a trial was initiated in December 2025, enrolling up to 227 participants in Australia.
The trial includes single and multiple ascending dose cohorts, with interim efficacy readout expected in H2 2026 and topline data in early 2027.
Efficacy endpoints include hair count, width, darkening, and patient-reported outcomes, focusing on durability and quality of life.
Dosing is subcutaneous every 2-3 months, aiming for >90% receptor occupancy and long-lasting effects.
Safety readout from the single ascending dose cohort will precede the 13-week efficacy data.
ABS-201 mechanism vs. current AGA treatments?
ABS-201 dual indication strategy?
H2 2026 interim data readout expectations?
What hair count increase targets ABS-201?
How will ABS-201 leverage the GLP-1 playbook?
Does ABS-201 cross the blood-brain barrier?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Absci earnings date
44th Annual J.P. Morgan Healthcare Conference14 Jan, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Absci Corporation operates as a generative AI drug creation company, focusing on revolutionizing the process of biologics drug discovery. Leveraging an integrated drug creation platform, Absci identifies novel drug targets and creates biotherapeutic candidates, shifting from traditional drug discovery to drug creation. This approach enables the design of de novo antibodies directly on computers, potentially reducing the development time for new drug leads and increasing their probability of success. The company's platform combines artificial intelligence with synthetic biology, allowing the construction and testing of millions of AI designs weekly. This innovative process results in wet lab-validated biologic-based therapeutics in a significantly shortened timeframe, aiming to address the challenges of traditionally high failure rates and lengthy development times in biologics drug discovery. The company is headquartered in Vancouver, Washington, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage